Muscular Dystrophy (MD)

Muscular Dystrophy (MD) is a group of genetic disorders characterized by progressive muscle degeneration and weakness. Unlike Motor Neuron Diseases (MND) such as ALS or SMA, MD primarily affects muscle cells themselves rather than the neurons that control them. MD is usually caused by mutations in genes related to muscle structure or function, preventing proper repair or maintenance of muscle tissue.

Overview

MD includes multiple subtypes, each with different onset ages, affected muscles, and progression rates. These disorders are typically progressive, leading to loss of mobility over time and sometimes affecting the heart and respiratory muscles. While incurable, treatments can slow symptoms and improve quality of life.

Common Types

1. Duchenne Muscular Dystrophy (DMD)
   • Most common and severe type, primarily in males (X-linked recessive).
   • Onset: 2–5 years.
   • Symptoms: walking difficulties (waddling, toe-walking), calf pseudohypertrophy, loss of ambulation by ~12 years, later heart and respiratory involvement.
   • Cause: mutation in the DMD gene → absence of dystrophin, a key structural protein.
   • Prognosis: survival usually into 20s–30s, death from heart or lung failure.
2. Becker Muscular Dystrophy (BMD)
   • Milder variant of DMD, dystrophin partially functional.
   • Onset: late childhood or adolescence.
   • Symptoms: similar to DMD but slower progression; many walk into adulthood.
   • Prognosis: lifespan 40–50+ years.
3. Limb-Girdle Muscular Dystrophy (LGMD)
   • Affects shoulder and pelvic muscles; caused by various gene mutations.
   • Onset: childhood to adulthood.
   • Symptoms: weakness in hips/shoulders, difficulty walking or lifting arms, sometimes heart involvement.
   • Prognosis: varies by subtype.
4. Facioscapulohumeral Muscular Dystrophy (FSHD)
   1. Affects face, shoulder blades, and upper arms.
   1. Onset: adolescence to adulthood.
   1. Symptoms: inability to close eyes or smile, winged scapula, arm weakness.
   1. Cause: abnormal expression in D4Z4 gene region.
   1. Prognosis: slow progression, lifespan usually normal.
5. Myotonic Dystrophy (DM)
   1. Most common adult-onset MD, with DM1 and DM2 subtypes.
   1. Symptoms: muscle stiffness (myotonia), weakness in limbs and face, systemic effects (heart disease, cataracts, diabetes).
   1. Cause: abnormal expansion of CTG or CCTG repeats.
   1. Prognosis: lifespan may be shortened depending on complications.

Symptoms

• Muscle weakness (starting in specific groups, spreading over time)
• Loss of motor function (difficulty walking, frequent falls, inability to run/jump)
• Muscle atrophy or pseudohypertrophy (fat replacing muscle tissue)
• Complications: cardiomyopathy, respiratory failure, joint contractures

Causes

• Genetic mutations, usually inherited.
• Inheritance patterns:
  • X-linked recessive (e.g., DMD, BMD → mostly males)
  • Autosomal recessive or dominant (e.g., LGMD, FSHD, DM)
• Mechanism: mutations disrupt muscle proteins (e.g., dystrophin, sarcoglycans), making muscle cells fragile or unable to regenerate.

Diagnosis

• Genetic testing: confirms mutations
• Muscle biopsy: shows structural abnormalities
• Blood tests: elevated creatine kinase (CK) levels
• Electromyography (EMG): distinguishes muscle vs. nerve disorders
• Family history and clinical evaluation

Treatment

No cure; focus on slowing progression and managing symptoms:

1. Medications
   • Steroids (Prednisone): slow DMD progression
   • Cardiac drugs (ACE inhibitors): protect heart
   • Anti-myotonia drugs (Mexiletine): relieve DM stiffness
2. Emerging therapies
   • Gene therapy (microdystrophin for DMD, in trials)
   • Exon skipping (Eteplirsen): enables partial dystrophin production
3. Supportive care
   • Physical therapy: maintain mobility, prevent contractures
   • Respiratory support: ventilators in late stages
   • Surgery: correct scoliosis, improve function

Prognosis

• DMD: most severe, survival ~20–30 years
• BMD & FSHD: slower progression, lifespan less affected
• DM: systemic complications may shorten lifespan
• Death often due to cardiac or respiratory failure

Differences from Motor Neuron Diseases

• MD: muscle degeneration itself
• SMA/ALS: neuron degeneration controlling muscles
• MD: no fasciculations or neuron-related symptoms
• MD: often childhood onset; ALS: adult onset

Latest Developments

• Gene editing (CRISPR) may one day repair DMD mutations
• Drug development (e.g., Ataluren) to boost protein production
• Patient support: early diagnosis and multidisciplinary care improve outcomes

Update: 1/5/2026